Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

102.95 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,328
Open 102.95
Bid (Size) 102.65 (5)
Ask (Size) 103.19 (1)
Prev. Close 102.95
Today's Range 102.95 - 102.95
52wk Range 86.02 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
These defensive index funds can help investors hedge against a possible recession. 
Via The Motley Fool
Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine
The COVID-19 vaccine put Moderna on the map, but its pipeline is going to be what keeps it there. 
Via The Motley Fool
Exposures COVID-19

Performance

YTD
-7.37%
-7.37%
1 Month
-6.27%
-6.27%
3 Month
-9.95%
-9.95%
6 Month
-5.44%
-5.44%
1 Year
+17.59%
+17.59%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Reasons to Buy Merck Stock
Via The Motley Fool
Check Out What Whales Are Doing With MRK
Via Benzinga
Why Shares of Iovance Biotherapeutics Jumped Monday
Via The Motley Fool
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
Via Benzinga
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
Via Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Via Benzinga
Why Is Seagen Stock Trading Higher Today?
Via Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Via Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
Via FinancialNewsMedia
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating
Via Benzinga
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.